Improving utilization of intravenous immune globulin through concurrent use of an indication form

Based on the guidelines of the United States Joint Commission for Accreditation of Health Care Organizations for conducting a drug utilization evaluation, we evaluated the usage of intravenous immune globulin at our tertiary care hospital. An initial concurrent evaluation of IVIG use showed deficien...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 1997-06, Vol.52 (4), p.255-260
Main Authors: FRAYHA, H. H, NUESSLE, S. J, ARISHI, H, RAYES, H, QUNIBI, W. Y, BAZARBASHI, M. S
Format: Article
Language:English
Subjects:
Biological and medical sciences
Drug development
Drug Labeling
Drug Utilization Review
Follow-Up Studies
Hospitals
Humans
Immunoglobulins
Immunoglobulins, Intravenous - therapeutic use
Immunomodulators
Immunosuppressive agents
Intravenous administration
Medical sciences
Pharmacology. Drug treatments
Practice Guidelines as Topic
Prospective Studies
Saudi Arabia
Studies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Based on the guidelines of the United States Joint Commission for Accreditation of Health Care Organizations for conducting a drug utilization evaluation, we evaluated the usage of intravenous immune globulin at our tertiary care hospital. An initial concurrent evaluation of IVIG use showed deficiencies in both dosing and compliance with hospital policy, with regards to its use for unlabeled indications. Two follow-up evaluations were performed after the institution of an IVIG indication form, which was designed to accompany each order. We demonstrated consistent improvements in both dosing criteria, labeled IVIG use, and compliance with hospital policy its use in unlabeled indications. An ongoing prospective program targeting IVIG use, combined with the introduction of a simple indication form improved its utilization at our hospital.
ISSN:0031-6970
1432-1041
DOI:10.1007/s002280050286